Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1).
Times cited: 63
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
Times cited: 53
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Journal of Clinical Oncology.
Times cited: 128